企業プロフィール
Vaxart 株価・ニュース・カタリスト
- ティッカー:
- VXRT
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.49 USD (-9.11%)
終値
最終更新: 2026年8月17日
—
時価総額
株価変動の要因
As of Aug 17, 2026, VXRT closed down 9.11% at $0.4940. No new same-company headline was identified in the current news window.
企業概要
Oral Vaccine Platform
Vaxart is a clinical-stage biotechnology company developing recombinant vaccines delivered as pills. Its platform is designed to eliminate injections and enable products that can be stored and shipped without refrigeration.
Mucosal Immunization Approach
The delivery technology combines an adenoviral vector with a TLR3 agonist to stimulate immune responses at mucosal surfaces. Vaxart aims to create oral alternatives to existing injectable vaccines and vaccines for indications without established products.
COVID-19 Program
The lead Phase 2b program compares Vaxart's oral COVID-19 vaccine with an approved mRNA vaccine. A 400-participant sentinel cohort assessed safety before analysis of the approximately 5,000-participant main cohort.
Broader Vaccine Pipeline
Additional development programs target norovirus and influenza, while a therapeutic HPV vaccine represents the platform's first immuno-oncology application.
今後のカタリスト
- Topline efficacy and safety results from the complete Phase 2b COVID-19 study in the first half of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。